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Background: The objective of this study was to retrospectively investigate and compare multidetector computed
tomography findings of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-positive and -negative patients.
Methods: Triphasic (arterial, portal venous, and delayed phases) dynamic multidetector computed tomography (CT)
was performed in 83 patients with HCC, 48 of whom were HBV-positive. The diagnosis of HCC was established with
typical CT imaging findings (68 patients) or histopathological evaluation (15 patients). Distribution of solitary, multiple,
and diffuse HCC, portal/hepatic vein thrombosis, metastasis, and patients with high alpha-fetoprotein levels in the
HBV-positive and -negative groups were compared using the Kolmogorov–Smirnov test. Lesion size, alpha-fetoprotein
levels, arterial, portal, delayed enhancement, and washout of lesions were compared using the Student’s t-test.
Results: Hypervascular tumors were observed in 72 (87%) patients, and hypovascular tumors were found in 11 (13%)
patients. The mean alpha-fetoprotein value of HBV-positive patients with HCC was significantly higher than the
mean alpha-fetoprotein value of HBV-negative patients (P < 0.05). Portal/hepatic vein thrombosis and metastasis
were more frequently observed in HBV-positive patients (P < 0.05). The frequencies of solitary, multiple, and diffuse
lesions in HBV-positive and -negative patients were not significantly different (P > 0.05). The mean diameters, arterial,
portal, and delayed phase attenuations, and washout of HCC were not significantly different (P > 0.05).
Conclusions: Multidetector CT imaging findings of HCC in HBV-positive and -negative patients are alike. Portal/hepatic
vein thrombosis and metastasis are more frequently observed in HBV-positive patients. Alpha-fetoprotein levels are
higher in HBV-positive patients.
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Hepatocellular carcinoma (HCC), which is the most com-
mon primary liver tumor, accounts for 85–90% of primary
liver cancers [1]. It is the third most common cause of can-
cer death and the fifth most common cancer worldwide.
HCC is generally associated with chronic parenchymal
liver disease, and the major risk factor for the development
of HCC is cirrhosis of the liver [2]. Emerging evidence
suggests that the etiology of many cases of HCC is
multifactorial, including both viral infections and non-
viral, environmental, and dietary exposures. Chronic* Correspondence: senem.senturk@yahoo.com
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unless otherwise stated.hepatitis B virus (HBV) infection is the primary risk factor
for the future development of HCC worldwide [3]. How-
ever, there are other important factors that may contribute
to the pathogenesis of HCC. In addition to chronic infec-
tion by HBV and C (HCV) viruses, an increased body
mass index and diabetes with the subsequent development
of non-alcoholic steatohepatitis (NASH) represent signifi-
cant risk factors for HCC. Other non-viral causes of HCC
include iron overload syndromes, alcohol use, tobacco
use, oral contraceptive use, and aflatoxin exposure [4].
HCC may be solitary, multifocal, or, less frequently,
diffusely infiltrative. Fatty change can be seen in up to
35% of HCCs [5]. The major diagnostic techniques forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Risk factors of hepatitis virus negative HCCs




Diabetes and hepatosteatosis 9
Hemochromatosis 1
No risk factor 11
NASH, non-alcoholic steatohepatitis.
Table 2 The frequency of elevated AFP values and mean
AFP values of HCC in HBV positive and negative patients




HBV positive 48 34 (71%) 460±80
HBV negative 35 24 (%68) 369±66
Total 83 58 (70%)
AFP, alpha-fetoprotein; HBV, hepatitis B virus.
Senturk et al. Cancer Imaging 2014, 14:9 Page 2 of 8
http://www.cancerimagingjournal.com/content/14/1/9HCC include serum markers, various imaging modalities,
and histologic analysis. Triphasic dynamic computed tom-
ography (CT) or magnetic resonance imaging (MRI) with
arterial, portal venous, and delayed phase imaging is con-
sidered to be the primary approach for the diagnosis of
HCC. Hepatocellular carcinomas are generally hypervas-
cular and are enhanced with the highest degree of contrast
during the arterial phase. Arterial phase imaging is effect-
ive in the detection of HCC, and dynamic CT, including
the arterial phase, is essential for the detection of HCC
[6-9]. Portal venous phase imaging is useful for detecting
hypovascular liver tumors, such as metastatic tumors from
the colorectum, because the liver parenchyma is enhanced
maximally during this phase [10]. For the detection of
HCCs, portal venous phase imaging is not sensitive be-
cause the tumors often show attenuation similar to that of
the enhanced liver parenchyma, thus resulting in de-
creased tumor conspicuity during this phase [7,9]. How-
ever, some hypovascular HCCs may be detected only on
portal venous phase images or may be depicted more con-
spicuously during this phase than the arterial phase. Portal
venous imaging is also useful for assessing portal venous
complications such as tumor thrombus [8]. Hepatocellular
carcinomas are often more conspicuous on delayed phase
images than on portal venous phase images, and detect-
ability and characterization are improved by adding de-
layed phase imaging to the biphasic CT examination
[7-9,11]. Capsule enhancement on delayed phase improves
the rates of detection of HCC [12].
Although the dynamic CT findings of HCC are well
defined, there are few studies to compare imaging find-
ings of HCCs of different etiologies [13,14]. Kim et al.
compared clinical and radiological findings of HCCs in
patients with chronic HBV and chronic HCV infections.
They found that lesions in patients with HBV were more
likely to be multifocal, larger than 5 cm, in non-nodular
shape, with atypical enhancement pattern, and in associ-
ation with portal vein thrombosis and bile duct invasion
[13]. The study by Butt et al. revealed that larger tumor
size, shorter duration between diagnosis of cirrhosis and
HCC, and concomitant diabetes mellitus were significant
factors associated with viral marker-negative HCC [14].
However, they did not compare imaging findings of viral
marker-positive and -negative HCCs. To our knowledge,
the dynamic CT imaging findings of HCCs of HBV-
positive and HBV-negative patients have not been com-
pared. We undertook this study to assess and compare
the triphasic, dynamic, multidetector CT (MDCT) im-
aging findings of the HCCs of HBV-positive and HBV-
negative patients.
Results and discussion
The risk factors of HBV-negative patients for HCC were
alcohol use (5 patients), tobacco use (17 patients), NASH(3 patients), diabetes and hepatosteatosis (9 patients), and
hemochromatosis (1 patient). Eleven patients had no risk
factors. The risk factors of HBV-negative patients are
listed in Table 1.
Thirty-four (71%) HBV-positive patients and 24 (68%)
HBV-negative patients had elevated alpha-fetoprotein
values. The mean alpha-fetoprotein level of HBV-positive
and -negative patients was 460 ± 80 ng/ml and 369 ±
66 ng/ml, respectively. The mean alpha-fetoprotein value
of HBV-positive patients with HCC was significantly
higher than the mean alpha-fetoprotein value of HBV-
negative patients (P < 0.05). However, the frequency of
elevated alpha-fetoprotein was not significantly different
between two groups (P > 0.05). The results are summa-
rized in Table 2.
All patients with HCC had at least one of the follow-
ing CT findings that showed evidence of chronic paren-
chymal liver disease: irregular liver contours, hepatic
volume loss and volume redistribution, coarse nodular
liver parenchyma. Cirrhosis was confirmed histopatho-
logically in 56 patients (67%).
Seventy-two patients (87%) had hypervascular tumors,
which were hyperattenuating on the arterial phase.
Forty-two (87.5% of HBV-positive cases) patients with
hypervascular tumors were HBV-positive and 30 (85.7%
of HBV-negative cases) were HBV-negative. They were
iso-hypoattenuating on the portal venous and delayed
phases (Figure 1). Four lesions (6%) could only be
depicted on the arterial phase. Sixty-eight (94%) hypervas-
cular lesions were hypoattenuating (showing washout) on
delayed phase images. Twenty-two (30%) hypervascular
Figure 1 Hypervascular hepatocellular carcinoma (arrows). The lesion is hyperdense on the arterial phase (a); however, it washes out and
becomes iso-hypodense on the portal phase images (b) and hypodense on the delayed phase images (c).
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phase. Biopsy was not required for hypervascular tumors
over 2 cm that washed out or showed capsule enhance-
ment on the delayed phase. HCC diagnosis was confirmed
histopathologically by biopsy in eight lesions of 1–2 cm.
Eleven (13%) patients, 7 of whom were HBV-positive, had
hypovascular tumors (Figure 2). Four (36%) patients had
hypovascular HCC lesions that showed capsule enhance-
ment on delayed phase images. These patients, who had
tumors > 2 cm, also had elevated alpha-fetoprotein levels,
and biopsy was not required. Seven patients with hypoat-
tenuating lesions were diagnosed by biopsy.
The typical CT findings of HCC were observed in
39 (81%) of HBV-positive patients, and 29 (83%) HBV-
negative patients. Fatty metamorphosis was depicted in four
patients (5%), three of which were HBV-positive (Figure 3).
The frequency of solitary lesions, multiple lesions, and
diffuse lesions in HBV-positive and -negative patients
are shown in Table 3. The difference was not statistically
significant (P > 0.05). Figure 4 shows the CT images of a
patient with diffusely infiltrative HCC and Figure 5 re-
veals multiple HCCs.
The frequencies of portal/hepatic vein thrombosis and
metastasis in HBV-positive and -negative patients are
shown in Table 4. Portal/hepatic vein thrombosis and me-
tastasis were more frequently observed in HBV-positive
patients (P < 0.05). Figure 6 shows a HCC lesion with por-
tal thrombosis and periportal metastatic lymphadenopathy.Figure 2 Hypovascular hepatocellular carcinoma (arrows). The lesion i
delayed (c) images.All patients with portal/hepatic vein thrombosis had
a tumor thrombus that revealed CT enhancement pat-
terns similar to HCCs. Non-tumoral, acute thrombus
was not observed; however, three patients, two of whom
were HBV-positive, had cavernous transformation of
the portal vein revealing a history of chronic bland
thrombus.
The most common metastatic site was lymph nodes in
both HBV-positive and -negative patients. Periportal and
para-aortic nodal metastases were observed in 12 patients,
10 of whom were HBV-positive. Four HBV-negative pa-
tients had metastases; two patients had lymph node me-
tastases, one had adrenal metastasis, and one had bone
metastases. Fourteen HBV-positive patients had extralym-
phatic metastases: 5 adrenal, 2 common bile duct, 2 lung,
3 bone, 1 renal, and 1 peritoneal.
The maximum diameter of the HCC lesions ranged
from 10 to 189 mm. The mean diameter of the HCC
lesions of HBV-positive patients was 77 ± 56 mm, and
the mean diameters of the HCC lesions of HBV-negative
patients was 65 ± 49 mm. The difference was not statisti-
cally significant (P > 0.05).
The mean arterial, portal, and delayed phase attenua-
tions, and the washout of HCC lesions of HBV-positive
and -negative patients, are shown in Table 5. The differ-
ences between attenuations and washout of HCCs in
HBV-positive and HBV-negative patients were not statis-
tically significant (P > 0.05).s hypodense and remains unenhanced on arterial (a), portal (b), and
Figure 3 Diffusely infiltrative hepatocellular carcinoma contains nodular fat (arrows). The large lesion invading both lobes of the liver
heterogeneously enhances on the arterial phase (a), and becomes isodense with focal hypodense areas on the portal venous phase (b).
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in cirrhosis may lead to chromosomal damage that initi-
ates hepatic carcinogenesis. In HBV-associated carcino-
genesis, viral factors are likely to be involved, and HCC
may occur in patients without significant background liver
fibrosis. There is strong epidemiological association be-
tween chronic HBV infection and HCC. Previous studies
showed that larger tumor size, shorter duration between
the diagnosis of cirrhosis and HCC were significant factors
associated with viral marker-negative HCC [14].
In this study, there was no difference between imaging
appearance (mean arterial, portal, and delayed phase at-
tenuations and washout degrees) of HCC lesions in
HBV-positive and -negative patients. Contrast enhance-
ment patterns, and the size and number of lesions were
alike. Thus, in this study, we did not observe a difference
between the MDCT imaging findings of the HCCs of
HBV-positive and -negative patients. To our knowledge,
the MDCT imaging findings of HBV-positive and -negative
patients has not been compared in previous studies.
We showed that tumor thrombus and metastases were
more common in HBV-positive patients. Vascular inva-
sion and tumor thrombus may lead to extrahepatic
spread of tumor cells; extensive resection and adjuvant
treatment may then be indicated. Since the occurrence
of vascular thrombus changes the surgical plan, HBV-
positive patients should be carefully evaluated to rule
out tumor thrombosis. In case of tumor thrombosis and
cavernous transformation of the main portal vein, liver
transplantation may not be possible.Table 3 The frequency of solitary lesions, multiple lesions,











HBV positive 22 (46%) 14 (29%) 12 (26%) 48
HBV negative 12 (34%) 12 (34%) 11 (32%) 35
HBV, hepatitis B virus.Alpha-fetoprotein has been used as a serum marker
for HCC for many years. Some patients with cirrhosis
and/or hepatic inflammation can have an elevated alpha-
fetoprotein, even without the presence of a tumor. In
previously published studies, the test has been shown to
have a sensitivity of 39–65%, a specificity of 76–94%,
and a positive predictive value of 9–50% for the presence
of HCC [15]. Trevisani et al. defined an alpha-fetoprotein
level of 16 ng/ml as the threshold that maximized sensitiv-
ity and specificity for the diagnosis of HCC [16]. Seventy
per cent of our patients had an alpha-fetoprotein
value > 16 ng/ml. The frequency of elevated alpha-
fetoprotein was not significantly different between
HBV-positive and -negative patients. However, the
mean alpha-fetoprotein value of HBV-positive patients
was significantly higher than the mean alpha-fetoprotein
value of HBV-negative patients. Metastases were more fre-
quent in HBV-positive patients. Moreover, HBV-positive
patients had HCCs with a larger mean diameter, which
might have caused higher alpha-fetoprotein values. How-
ever, it should be noted that the size of lesions ranged from
10 mm to 189 mm, and that the difference between the
mean lesion size of the two groups was not significant due
to such a wide range.
Ishikawa suggested that HBV-related HCC may occur
in younger patients with mild inflammation and fibrosis
than in patients with HCV-related HCC [3]. However, in
many cases of HBV-related HCC, the tumor stage is
advanced, presenting an undifferentiated cancer type
with portal vein infiltration, suggesting that HBV-related
HCC has a worse prognosis and a more refractory charac-
ter than HCV-related HCC [3]. Moreover, HBV-related
HCC is infiltrative, showing multinodular growth, unlike
HCV-related HCC [17]. HBV-related HCC is often ac-
companied by portal vein tumor thrombus [3]. We also
observed portal/hepatic vein thrombosis and metastasis
more frequently in HBV-positive patients, supporting that
advanced disease stage is more common in HBV-related
HCC. In this study, we could not compare HBV-positive
and HCV-positive patients, because most HCV-positive
Figure 4 Diffusely infiltrative hepatocellular carcinoma. The heterogeneous lesion invades both lobes of the liver and mildly enhances on
the arterial phase (a). The portal venous phase image (b) shows a hypodense, infiltrative lesion with multiple small hypodense satellite nodules.
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tients were excluded from the study group. We found only
five HCV-positive patients without HBV. Because of this
small number, these patients were also excluded from the
study group.
Our study has some limitations. We had a small sam-
ple size and limited histopathologic correlation. The
major risk factors for HBV-negative HCCs could not be
clearly identified. Some patients had no risk factors,
whereas some had more than one risk factor. HBV-
negative patients were composed of a heterogeneous
patient group. Another limitation was the lack of histo-
pathological diagnosis of cirrhosis in some patients;
however, all patients showed CT evidence of chronic
parenchymal liver disease. Prospective studies with lar-
ger patient cohorts are necessary to clearly define the
risk factors of HBV-negative patients, and compare the
CT imaging findings and clinical outcomes of these pa-
tients. Because of the retrospective design of the study,
we could not compare the clinical outcomes of HBV-
positive and -negative patients.
Conclusion
We have shown that the MDCT imaging findings of HCCs
of HBV-positive and -negative patients were alike. In this
study, we observed that the frequency of elevated alpha-
fetoprotein was not different between HBV-positive andFigure 5 Multiple hepatocellular carcinomas. Two lesions in the right lo
wash out and become hypodense on the delayed phase image (b). The pa-negative patients; however, the mean alpha-fetoprotein
value of the HBV-positive patients was higher. Portal/
hepatic vein thrombosis and metastasis were more fre-
quent in HBV-positive patients.
Methods
Patients and hepatocellular carcinoma diagnosis
A retrospective review of the computer-based radiology
archive of Dicle University was performed to determine
patients with HCCs who had undergone dynamic liver
MDCT. HCCs with either typical dynamic CT imaging
findings or histopathologic diagnosis were included in
the study. We excluded patients with either a positive
serology for HCV or a technically inadequate CT exam-
ination. We excluded three patients because of technic-
ally inadequate examinations with artifacts. We found
that 65 consecutive HBV-positive patients with HCCs
had undergone technically adequate dynamic MDCT be-
tween January 2007 and June 2009. Seventeen patients
were excluded from the study group because they were
also HCV-positive. Since HCCs were much more com-
mon in patients with HBV, we had to review the radiology
archive for a longer period to find a large-enough number
of HBV-negative patients. Forty consecutive HBV-negative
patients with HCCs had undergone technically adequate
dynamic MDCT between January 2007 and December.
Due to HCV infection, five patients were excluded.be of the liver are hyperdense on the arterial phase (a); however, they
tient also had two lesions in the left lobe of the liver (not shown).
Table 4 The frequency of portal and/or hepatic venous




No of patients with portal
and/or hepatic venous
thrombus (%)
No of patients with
metastasis (%)
HBV positive 20 (%42) 15 (%31)
HBV negative 8 (%23) 4 (%11)
HBV, hepatitis B virus.
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women; age range, 49–85 years; mean age, 66 years) with
HCCs either diagnosed by MDCT findings or histopatho-
logically by biopsy. Forty-eight patients were HBV-positive
and 35 patients were HBV-negative. The risk factors of
HBV-negative patients were searched from their hospital
records. The alpha-fetoprotein values of all patients were
recorded. An alpha-fetoprotein level of 16 ng/ml was used
as the threshold.
HCC lesions greater than 2 cm in diameter can be di-
agnosed non-invasively, based on radiographic criteria in
patients with cirrhosis [18]. Histologic confirmation by
biopsy is not mandatory owing to the excellent diagnostic
accuracy of imaging criteria and the 10–20% false-
negative rate from histologic samples [19]. Recent stud-
ies concluded that in cirrhotic patients and patients
with chronic hepatitis B, nodules greater than 1 cm in
diameter that reveal the typical features of HCC on dy-
namic profile (arterial hypervascularity with washout in
the portal or delayed venous phase) can be diagnosed as
HCC by using a single imaging modality [20]. Histologic
diagnosis is recommended if the vascular pattern is not
characteristic for HCC on imaging modalities, to estab-
lish the diagnosis [20].
In this study, the diagnosis of HCC was based on im-
aging findings in 68 patients, 39 of whom were HBV-Figure 6 Portal vein thrombosis (black arrows) and periportal-parace
lymphadenopathies are hypervascular similar to the hepatocellular carcinom
and lymphadenopathies wash out on the portal venous phase (b).positive. Image analysis was performed by a radiologist
(SS) who had 6 years’ experience in abdominal imaging.
Sixty-eight patients had HCCs over 2 cm in diameter
that revealed typical dynamic CT findings (either arterial
hypervascularity with washout in the portal or delayed
venous phase or typical capsule enhancement on delayed
phase). Since CT findings were inconclusive in 15 patients
(8 patients with hypervascular lesions of 1–2 cm, 7 patients
with hypovascular lesions > 2 cm), ultrasound-guided fine
needle aspiration biopsy (FNAB) and histopathologic diag-
nosis was required. Two HBV-positive patients (13%) re-
quired repeated FNAB, because the initial procedure was
not diagnostic. Histopathological analysis was performed
by a pathologist (SO) who had 11 years’ experience in liver
pathologies. Radiologic-pathologic correlation was per-
formed by the same radiologist and pathologist who estab-
lished diagnosis of HCC.
To evaluate abdominal metastasis, portal phase CT im-
ages covering the whole abdomen from the diaphragm to
the symphysis pubis were investigated. When HCC diag-
nosis was established, chest CT and bone scintigraphy
were also performed to evaluate further metastases.Computed tomography scanning protocol and image
assessment
All studies were performed on a CT scanner with 64 detec-
tors (Brilliance CT 64-channel scanner; Philips Medical
Systems Inc., Cleveland, OH, USA). An 18–20 gauge angio-
catheter was introduced into the antecubital vein of each
patient. The administration rate was 4 ml/s; 300 mg/ml
of 100–150 cc (1–2 ml/kg) nonionic iodine solution
was used as the contrast medium. Dose parameters
were 250–300 mAs and 120 kV. The scan parameters
were as follows: reconstruction interval 1.5, slice thick-
ness 3 mm, pitch factor 0.79–1.11, rotation time 0.5 s,
collimation 64 × 0.625.liac lymphadenopathies (white arrows). On the arterial phase (a),
a in the right lobe of the liver (asterisk). The hepatocellular carcinoma
Table 5 Mean arterial, portal, delayed phase attenuations

















100±20 74±12 60±12 39±17
HBV
negative
99±22 73±10 62±11 36±20
HBV, hepatitis B virus; HU, Hounsfield unit.
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performed during the hepatic arterial phase, portal ven-
ous phase, and delayed phase. Arterial phase imaging
was performed 20 s after the start of the contrast mater-
ial injection. The delay time was 50 s for portal venous
phase imaging and 3 min for delayed phase imaging. All
studies were started at the top of the liver and proceeded
in a cephalocaudal direction; arterial phase and delayed
phase, contrast-enhanced helical scans of the entire liver
were obtained. The whole abdomen, from diaphragm to
symphysis pubis, was scanned at the portal venous
phase. Patients were asked to hold their breath during
scanning.
Arterial enhancement, portal venous enhancement,
and washout of lesions were measured for each lesion.
Three measurements were performed on transverse,
3-mm reconstructed images, with no intersectional gap
for each phase set. Mean CT values in Hounsfield units
(HUs) in the HCC lesions were measured in all patients
on the workstation (Extended Brilliance Workspace;
Philips Healthcare, Best, The Netherlands) by using a
circular region-of-interest cursor ranging in size from
5 to 30 mm in diameter. Measurements were performed
on the arterial, portal, and delayed phase images (Figure 7).
For heterogeneously enhancing lesions, arterial phase
measurements were performed from the most enhancingFigure 7 Measurements of computed tomography (CT) attenuations (
on arterial (a) and delayed (b) phase CT images.portion, and on portal venous and delayed phases the
same portion of the lesion was used for the measure-
ments. When there was more than one lesion, mean
values were calculated for each patient.
The number of solitary, multiple, and diffuse HCC le-
sions was determined. Whole-abdomen images of the
portal phase were reviewed to search for portal/hepatic
vein thrombosis and metastasis. The maximum diame-
ters of all lesions were measured. When there was more
than one lesion, mean values were calculated for each
patient.Statistical analysis
The SPSS software package, version 11.01 (SPSS Inc.,
Chicago, IL, USA), was used for data analysis and a
P value of 0.05 was considered statistically significant.
Data were presented as mean ± standard deviation.
The frequency of elevated alpha-fetoprotein was calcu-
lated as a percentage for HBV-positive and -negative pa-
tients. The alpha-fetoprotein values of the two groups
were compared using the Student’s t-test. The distri-
bution of elevated alpha-fetoprotein levels in HBV-
positive and -negative patients were compared using
the Kolmogorov–Smirnov test.
The frequencies of solitary, multiple, and diffuse HCCs,
and the portal and hepatic venous thrombosis and metas-
tasis were determined in HBV-positive and -negative pa-
tients. The distribution of lesion numbers, thrombosis and
metastasis in the two groups (HBV-positive and -negative
patients) were compared using the Kolmogorov–Smirnov
test.
Arterial enhancement, portal venous enhancement and
washout values of lesions were compared using the
Student’s t-test. The washout was calculated by sub-
traction of delayed phase HU values from arterial
phase HU values (washout (HU) = arterial phase en-
hancement (HU) - delayed phase enhancement (HU)).in Hounsfield units) of a hypervascular hepatocellular carcinoma
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